Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN.c has been granted Orphan Drug Designation to Ifenprodil

<< Previous

Bullboard Posts

Next >>

Comment by XeniaTechieon Dec 06, 2022 1:21pm

109 Views

Post# 35153871

RE:AGN.c has been granted Orphan Drug Designation to Ifenprodil

Major catalyst alert re: Algernon’s recent news being granted orphan drug designation by the FDA for its use of Ifenprodil as a treatment for IPF.

FDA orphan drug designation is massive due to the potential 7-year exclusivity following approval. Can't wait for the next updates as they progress through the next steps of their clinical program.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources